Published in Eur J Neurosci on January 01, 2004
Prevention or modification of epileptogenesis after brain insults: experimental approaches and translational research. Pharmacol Rev (2010) 1.68
The potential of antiseizure drugs and agents that act on novel molecular targets as antiepileptogenic treatments. Neurotherapeutics (2014) 0.93
Early life stress as an influence on limbic epilepsy: an hypothesis whose time has come? Front Behav Neurosci (2009) 0.92
Levetiracetam attenuates hippocampal expression of synaptic plasticity-related immediate early and late response genes in amygdala-kindled rats. BMC Neurosci (2010) 0.90
Attenuation of kindled seizures by intranasal delivery of neuropeptide-loaded nanoparticles. Neurotherapeutics (2009) 0.85
Levetiracetam inhibits Na+-dependent Cl-/HCO3- exchange of adult hippocampal CA3 neurons from guinea-pigs. Br J Pharmacol (2004) 0.83
Anti-inflammatory effects of the anticonvulsant drug levetiracetam on electrophysiological properties of astroglia are mediated via TGFβ1 regulation. Br J Pharmacol (2011) 0.82
Region-specific changes in gene expression in rat brain after chronic treatment with levetiracetam or phenytoin. Epilepsia (2010) 0.80
Synaptic Vesicle Glycoprotein 2A Ligands in the Treatment of Epilepsy and Beyond. CNS Drugs (2016) 0.76
SV2A: more than just a new target for AEDs. Epilepsy Curr (2005) 0.75
The neurobiology of antiepileptic drugs. Nat Rev Neurosci (2004) 3.24
Drug resistance in brain diseases and the role of drug efflux transporters. Nat Rev Neurosci (2005) 3.19
Globular amyloid beta-peptide oligomer - a homogenous and stable neuropathological protein in Alzheimer's disease. J Neurochem (2005) 3.06
The blood-brain barrier and cancer: transporters, treatment, and Trojan horses. Clin Cancer Res (2007) 3.04
Blood-brain barrier active efflux transporters: ATP-binding cassette gene family. NeuroRx (2005) 2.44
Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases. Prog Neurobiol (2005) 2.43
Functional inactivation of a fraction of excitatory synapses in mice deficient for the active zone protein bassoon. Neuron (2003) 2.31
Structural characterization of a soluble amyloid beta-peptide oligomer. Biochemistry (2009) 2.31
The immunogenetics of smallpox vaccination. J Infect Dis (2007) 2.23
The completion of the Mammalian Gene Collection (MGC). Genome Res (2009) 2.21
Systematic identification of type I and type II interferon-induced antiviral factors. Proc Natl Acad Sci U S A (2012) 2.18
Expression of interneuron markers in the dorsolateral prefrontal cortex of the developing human and in schizophrenia. Am J Psychiatry (2010) 2.01
Seizure-induced up-regulation of P-glycoprotein at the blood-brain barrier through glutamate and cyclooxygenase-2 signaling. Mol Pharmacol (2007) 1.97
Hereditary spastic paraplegias with autosomal dominant, recessive, X-linked, or maternal trait of inheritance. J Neurol Sci (2012) 1.97
A critical analysis of the clinical use of incretin-based therapies: Are the GLP-1 therapies safe? Diabetes Care (2013) 1.90
The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions. Nat Med (2004) 1.89
Seizure recurrence after planned discontinuation of antiepileptic drugs in seizure-free patients after epilepsy surgery: a review of current clinical experience. Epilepsia (2004) 1.87
Drug resistance in epilepsy: putative neurobiologic and clinical mechanisms. Epilepsia (2005) 1.86
An online database for brain disease research. BMC Genomics (2006) 1.76
New avenues for anti-epileptic drug discovery and development. Nat Rev Drug Discov (2013) 1.63
Role of multidrug transporters in pharmacoresistance to antiepileptic drugs. J Pharmacol Exp Ther (2002) 1.60
A pilot study to assess the efficacy of tariquidar to inhibit P-glycoprotein at the human blood-brain barrier with (R)-11C-verapamil and PET. J Nucl Med (2009) 1.56
Amyloid beta oligomers (A beta(1-42) globulomer) suppress spontaneous synaptic activity by inhibition of P/Q-type calcium currents. J Neurosci (2008) 1.54
Therapeutic window of opportunity for the neuroprotective effect of valproate versus the competitive AMPA receptor antagonist NS1209 following status epilepticus in rats. Neuropharmacology (2011) 1.53
Symptomatic and asymptomatic benign prostatic hyperplasia: molecular differentiation by using microarrays. Proc Natl Acad Sci U S A (2002) 1.53
Mutations in the SPTLC2 subunit of serine palmitoyltransferase cause hereditary sensory and autonomic neuropathy type I. Am J Hum Genet (2010) 1.52
Prefrontal GABA(A) receptor alpha-subunit expression in normal postnatal human development and schizophrenia. J Psychiatr Res (2010) 1.50
Several major antiepileptic drugs are substrates for human P-glycoprotein. Neuropharmacology (2008) 1.48
Lack of association between adrenergic receptor genotypes and survival in heart failure patients treated with carvedilol or metoprolol. J Am Coll Cardiol (2008) 1.46
Identification of new epilepsy treatments: issues in preclinical methodology. Epilepsia (2012) 1.45
Differential effects of cation-chloride co-transport-blocking diuretics in a rat hippocampal slice model of epilepsy. Epilepsy Res (2006) 1.45
Tariquidar-induced P-glycoprotein inhibition at the rat blood-brain barrier studied with (R)-11C-verapamil and PET. J Nucl Med (2008) 1.44
Anticonvulsant effects of transcranial direct-current stimulation (tDCS) in the rat cortical ramp model of focal epilepsy. Epilepsia (2006) 1.41
Behavioral alterations in the pilocarpine model of temporal lobe epilepsy in mice. Exp Neurol (2007) 1.40
Reduced spine density in specific regions of CA1 pyramidal neurons in two transgenic mouse models of Alzheimer's disease. J Neurosci (2011) 1.36
The multidrug transporter hypothesis of drug resistance in epilepsy: Proof-of-principle in a rat model of temporal lobe epilepsy. Neurobiol Dis (2006) 1.33
Disease-modifying effects of phenobarbital and the NKCC1 inhibitor bumetanide in the pilocarpine model of temporal lobe epilepsy. J Neurosci (2010) 1.29
SV2A protein is a broad-spectrum anticonvulsant target: functional correlation between protein binding and seizure protection in models of both partial and generalized epilepsy. Neuropharmacology (2007) 1.23
Dose-response assessment of tariquidar and elacridar and regional quantification of P-glycoprotein inhibition at the rat blood-brain barrier using (R)-[(11)C]verapamil PET. Eur J Nucl Med Mol Imaging (2009) 1.23
A Bronchial Genomic Classifier for the Diagnostic Evaluation of Lung Cancer. N Engl J Med (2015) 1.22
Synthesis and in vivo evaluation of [11C]tariquidar, a positron emission tomography radiotracer based on a third-generation P-glycoprotein inhibitor. Bioorg Med Chem (2010) 1.20
Generation and therapeutic efficacy of highly oligomer-specific beta-amyloid antibodies. J Neurosci (2010) 1.20
Mitochondrial DNA variants of respiratory complex I that uniquely characterize haplogroup T2 are associated with increased risk of age-related macular degeneration. PLoS One (2009) 1.19
Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein. Neuropharmacology (2006) 1.18
Is Alzheimer's disease a result of presynaptic failure? Synaptic dysfunctions induced by oligomeric beta-amyloid. Rev Neurosci (2009) 1.15
Multidrug resistance protein MRP2 contributes to blood-brain barrier function and restricts antiepileptic drug activity. J Pharmacol Exp Ther (2003) 1.14
Behavioral and cognitive alterations, spontaneous seizures, and neuropathology developing after a pilocarpine-induced status epilepticus in C57BL/6 mice. Exp Neurol (2009) 1.13
Neurogenesis in the adult rat piriform cortex. Neuroreport (2006) 1.12
Prophylactic treatment with levetiracetam after status epilepticus: lack of effect on epileptogenesis, neuronal damage, and behavioral alterations in rats. Neuropharmacology (2007) 1.11
The COX-2 inhibitor parecoxib is neuroprotective but not antiepileptogenic in the pilocarpine model of temporal lobe epilepsy. Exp Neurol (2010) 1.11
Effects of the novel antiepileptic drug levetiracetam on spontaneous recurrent seizures in the rat pilocarpine model of temporal lobe epilepsy. Epilepsia (2002) 1.11
Comparison of brain extracellular fluid, brain tissue, cerebrospinal fluid, and serum concentrations of antiepileptic drugs measured intraoperatively in patients with intractable epilepsy. Epilepsia (2006) 1.10
Localization and photoaffinity labelling of the levetiracetam binding site in rat brain and certain cell lines. Eur J Pharmacol (2003) 1.10
Synthesis and small-animal positron emission tomography evaluation of [11C]-elacridar as a radiotracer to assess the distribution of P-glycoprotein at the blood-brain barrier. J Med Chem (2009) 1.09
Genetically engineered GABA-producing cells demonstrate anticonvulsant effects and long-term transgene expression when transplanted into the central piriform cortex of rats. Exp Neurol (2002) 1.08
Immunohistochemical localization of P-glycoprotein in rat brain and detection of its increased expression by seizures are sensitive to fixation and staining variables. J Histochem Cytochem (2005) 1.07
High resolution ultrasound in posterior interosseous nerve syndrome. Muscle Nerve (2013) 1.07
Treatment with valproate after status epilepticus: effect on neuronal damage, epileptogenesis, and behavioral alterations in rats. Neuropharmacology (2006) 1.06
Evaluation of transport of common antiepileptic drugs by human multidrug resistance-associated proteins (MRP1, 2 and 5) that are overexpressed in pharmacoresistant epilepsy. Neuropharmacology (2010) 1.06
Valproic acid is not a substrate for P-glycoprotein or multidrug resistance proteins 1 and 2 in a number of in vitro and in vivo transport assays. J Pharmacol Exp Ther (2006) 1.05
P-Glycoprotein-mediated efflux of phenobarbital, lamotrigine, and felbamate at the blood-brain barrier: evidence from microdialysis experiments in rats. Neurosci Lett (2002) 1.05
COX-2 inhibition controls P-glycoprotein expression and promotes brain delivery of phenytoin in chronic epileptic rats. Neuropharmacology (2009) 1.03
A novel positron emission tomography imaging protocol identifies seizure-induced regional overactivity of P-glycoprotein at the blood-brain barrier. J Neurosci (2011) 1.02
Resistance to antiepileptic drugs and expression of P-glycoprotein in two rat models of status epilepticus. Epilepsy Res (2008) 1.01
Anticonvulsant effects of levetiracetam and levetiracetam-diazepam combinations in experimental status epilepticus. Epilepsy Res (2004) 1.00
Pilocarpine vs. lithium-pilocarpine for induction of status epilepticus in mice: development of spontaneous seizures, behavioral alterations and neuronal damage. Eur J Pharmacol (2009) 1.00
Putative psychosis genes in the prefrontal cortex: combined analysis of gene expression microarrays. BMC Psychiatry (2008) 1.00
Molecular evidence that cortical synaptic growth predominates during the first decade of life in humans. Int J Dev Neurosci (2010) 1.00
Proepileptic phenotype of SV2A-deficient mice is associated with reduced anticonvulsant efficacy of levetiracetam. Epilepsia (2009) 1.00
Finding a better drug for epilepsy: antiepileptogenesis targets. Epilepsia (2012) 0.99
Increased slow oscillatory activity in substantia nigra pars reticulata triggers abnormal involuntary movements in the 6-OHDA-lesioned rat in the presence of excessive extracellular striatal dopamine. Neurobiol Dis (2006) 0.99
Modulation of neurogenesis by targeted hippocampal irradiation fails to affect kindling progression. Hippocampus (2010) 0.98
BH3 profiling discriminates response to cytarabine-based treatment of acute myelogenous leukemia. Mol Cancer Ther (2013) 0.97
The intrahippocampal kainate model of temporal lobe epilepsy revisited: epileptogenesis, behavioral and cognitive alterations, pharmacological response, and hippoccampal damage in epileptic rats. Epilepsy Res (2012) 0.97
Characterization of 7- and 19-month-old Tg2576 mice using multimodal in vivo imaging: limitations as a translatable model of Alzheimer's disease. Neurobiol Aging (2010) 0.96
Desynchronizing effect of levetiracetam on epileptiform responses in rat hippocampal slices. Neuroreport (2003) 0.96
Alzheimer's disease-like neuropathology of gene-targeted APP-SLxPS1mut mice expressing the amyloid precursor protein at endogenous levels. Neurobiol Dis (2005) 0.96
Effects of the novel antiepileptic drug lacosamide on the development of amygdala kindling in rats. Epilepsia (2006) 0.96
Assessment of regional differences in tariquidar-induced P-glycoprotein modulation at the human blood-brain barrier. J Cereb Blood Flow Metab (2009) 0.96
Finding a better drug for epilepsy: preclinical screening strategies and experimental trial design. Epilepsia (2012) 0.95
Targeting prostaglandin E2 EP1 receptors prevents seizure-associated P-glycoprotein up-regulation. J Pharmacol Exp Ther (2009) 0.95
Behavioral alterations in a mouse model of temporal lobe epilepsy induced by intrahippocampal injection of kainate. Exp Neurol (2008) 0.95
Development of new treatment approaches for epilepsy: unmet needs and opportunities. Epilepsia (2013) 0.94
Prevention of seizure-induced up-regulation of endothelial P-glycoprotein by COX-2 inhibition. Neuropharmacology (2009) 0.94
Developmental co-regulation of the beta and gamma GABAA receptor subunits with distinct alpha subunits in the human dorsolateral prefrontal cortex. Int J Dev Neurosci (2010) 0.93
(R)-[(11)C]verapamil is selectively transported by murine and human P-glycoprotein at the blood-brain barrier, and not by MRP1 and BCRP. Nucl Med Biol (2013) 0.93
Differences in the expression of endogenous efflux transporters in MDR1-transfected versus wildtype cell lines affect P-glycoprotein mediated drug transport. Br J Pharmacol (2010) 0.93
Targeting epileptogenesis-associated induction of neurogenesis by enzymatic depolysialylation of NCAM counteracts spatial learning dysfunction but fails to impact epilepsy development. J Neurochem (2008) 0.93